Compared to Estimates, Danaher (DHR) Q4 Earnings: A Look at Key Metrics

Core Insights - Danaher reported revenue of $6.84 billion for the quarter ended December 2025, reflecting a year-over-year increase of 4.6% and a surprise of +0.64% over the Zacks Consensus Estimate of $6.79 billion [1] - The company's EPS for the quarter was $2.23, up from $2.14 in the same quarter last year, with an EPS surprise of +0.68% compared to the consensus estimate of $2.22 [1] Financial Performance Metrics - Organic sales growth was 2.5%, exceeding the average estimate of 1.8% from six analysts [4] - Total sales in the Biotechnology segment reached $2.03 billion, slightly above the five-analyst average estimate of $2.02 billion, representing a year-over-year increase of +8.8% [4] - Total sales in the Diagnostics segment were $2.72 billion, surpassing the estimated $2.7 billion, with a year-over-year change of +3.2% [4] - Life Sciences segment sales amounted to $2.09 billion, compared to the average estimate of $2.06 billion, reflecting a +2.6% year-over-year change [4] - Operating profit in the Biotechnology segment was $540 million, exceeding the estimated $535.78 million [4] - Operating profit for Diagnostics was $713 million, above the average estimate of $690.13 million [4] - Life Sciences operating profit reached $336 million, significantly higher than the average estimate of $258.78 million [4] - The stock has returned +2.2% over the past month, outperforming the Zacks S&P 500 composite's +0.8% change, and currently holds a Zacks Rank 2 (Buy) [3]